🚀 Mission View
A sharper perspective on this week's issue that matters at the intersection of health and AI.
A few months ago, on another platform, I wrote about how AI is reshaping drug development. This week’s FDA/CTTI workshop showed just how quickly that shift is accelerating. You can check out the agenda for the workshop here.
As the FDA’s Shantanu Nundy put it: “We don’t want just a faster horse. We want to build a car.” Regulators are now talking about synthetic disease registries, AI models that could replace animal studies, and AI-designed clinical trials.
The FDA is also investing in agency-wide AI tools to speed up its own review process (jury’s still out on how well they work). Meanwhile, AstraZeneca just signed a $555M deal with Algen Biotechnologies to use AI for gene editing — a sign that industry isn’t waiting for policy to catch up.
But here’s the question I keep coming back to: if AI is shortening the path from lab bench to bedside, how do we make sure that value actually reaches consumers? Are we building faster pipelines just to deliver the same prices, or are we ready to rethink how innovation and value are shared?
🛜 Field Signals
A quick hit on this week’s key policy shifts and industry trends.
OpenAI announced that they were introducing parental controls with mental health notifications.
Center-left think-tank, Third Way, is out with a new report examining AI and emerging tech in healthcare.
Washington Post opinion writer (who focuses on health issues) pens a new piece on the promise (and perils) of AI in healthcare.
This Health Affairs Forefront article on how AI could help turbo-charge CMS’ value-based care agenda.
MedCity News: The Future of AI in Healthcare Depends on Clinical Data Quality Assessment
Forbes: The Barrier To Wide-Scale AI Adoption In Healthcare Is Trust, Not Technology
STAT: Trump administration escalates assault on Coalition for Health AI, as Amazon drops out.
Also from STAT: Top Democrat demands more detail from Medicare insurers about their use of AI
Converseley, CMS and Dr. Oz are taking a more hands-off approach to regulating Medicare insurers and AI - but are ready to pounce if need be.
Speaking of AI and Medicare, flagging this Health Affairs Forefront article on the WiSER model that has been proposed, which relies on using AI in FFS Medicare.
🛠️ Practical Edge
Actionable tips and tools to help leaders strengthen capacity and apply AI in their work.
A leader’s roadmap to enterprise AI governance and training — This new guide outlines how organizations can create responsible AI policies, set up governance frameworks, and train staff to use AI effectively. For mission-driven health organizations, it’s a practical starting point for getting ahead of regulation — and building the confidence and accountability structures needed before AI use scales across teams.
Monologue converts your voice into polished, well-formatted text — casual when you want it to sound human, professional when it needs to sound sharp. Free for your first 1K words, then $100/year (early-bird pricing). For health teams juggling notes, summaries, and reports, this could be an easy way to turn spoken ideas into ready-to-send content — saving time without sacrificing tone.
🌅 On the Horizon
A quick look at the developments and events expected to shape the weeks ahead.
Oct. 16: Crowell & Moring is hosting a webinar on the fast-evolving AI regulatory landscape, from the White House’s “America’s AI Action Plan” to a wave of new state laws in healthcare, labor, and privacy. The session will unpack compliance risks, federal–state tensions, and what organizations should expect next. Register here.
Oct. 21-22: TedAI San Francisco.
Oct. 22-23: PyTorch Conference in San Francisco. Register here.
Dec. 8-9: Fortune Brainstorm AI San Francisco. Apply to attend here.
⌚️ Closing Time
A parting thought on what health leaders need to be focused on.
At last week’s Senate HELP hearing, witnesses and Senators agreed on two things: AI can boost care and reduce admin drag, and humans still need to stay in the loop.
Care delivery: AI is helping with imaging, documentation, and trial design, but clinicians must retain judgment. Sen. Markey previewed a “Right to Override” concept so staff can reject unsafe AI outputs without retaliation.
Small and rural systems: Big upside on cost and workflow, big downside in tool sprawl. Hospitals need help with vetting and shared best practices.
Biosecurity and safety: AI lowers design timelines. Lawmakers pushed for tiered access, auditing, and traceability of risky queries.
Liability and governance: Open questions on who pays when AI advice goes wrong. Expect pressure for principle-based rules, faster guidance cycles, and more transparency.
What’s the take away for your organization? Keep humans in charge, stand up a lightweight AI oversight process, and join or borrow from shared vetting networks so smaller teams are not evaluating tools alone. Document an explicit “right to override” in policy and training.
Till next time,
